Leggy A. Arnold is a Professor of Chemistry and Biochemistry at the University of Wisconsin Milwaukee (UWM) and a founding member of the Milwaukee Institute for Drug Discovery (MIDD). He received his Ph.D. degree from the University of Groningen (NL) under Nobel Laureate Professor Ben Feringa in 2002. His research resulted in the development of one of the most selective catalysts for the enantioselective 1,4-addition and he introduced the first catalytic enantioselective methodology to synthesize prostaglandins. His postdoctoral research at the University of California San Francisco in the research laboratory of Dr. Kip Guy let to the discovery of the first transcriptional inhibitors of the thyroid receptor – coregulatory interactions. In 2005, he started at St. Jude Children’s Research Hospital and supported the founding of the Department of Chemical Biology and Therapeutics. In 2009, Dr. Arnold started his academic career at UWM and quickly advanced as an expert in the field of vitamin D research. He developed new potent anti-tumor agents for ovarian cancer and leukemia that have been patented and licensed. His recent focus on targeting peripheral GABA(A) receptors outside the CNS to treated inflammation and bronchoconstriction resulted in a clinical asthma candidate MIDD0301. In 2017, he founded Pantherics together with Dr. Douglas Stafford and has transformed Pantherics as a Chief Scientific Officer to a small business with headquarter in La Jolla, California.